EUCTR2006-003173-27-AT进行中（未招募）不适用
A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 155
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •= 18 years of age
- •Estimated GFR of = 15 mL/min/1.73 m2 - = 60 mL/min/1.73 m2 (MDRD equation)
- •Clinically stable, in the judgment of the investigator
- •The mean of 2 screening Hb values taken at least 7 days apart must be <11.0 g/dL
- •Adequate iron stores (serum ferritin > 100 µg/L)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Scheduled to receive a kidney transplant
- •ESA use within 12 weeks before enrollment
- •Uncontrolled hypertension defined as diastolic BP > 110 mm Hg or systolic BP >180 mm Hg
- •Acute myocardial ischemia; hospitalization for congestive heart failure, myocardial infarction, deep vein thrombosis, stroke or transient ischemic attack within 12 weeks before enrollment
- •Major surgery within 12 weeks before enrollment (excluding vascular access
- •Currently receiving antibiotic therapy for systemic infection.
- •Known positive HIV antibody or positive hepatitis B surface antigen
- •Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
- •Red blood cell (RBC) transfusions within 8 weeks before enrollment
- •Androgen therapy within 8 weeks before enrollment
- •Systemic hematological disease (eg, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy; myeloma; hemolytic anemia)
- •Any disorder that may impact (in the judgment of the investigator) the ability to give informed consent for participation in this study
- •Pregnant or breast-feeding women. All subjects must practice adequate
- •contraception (in the judgment of the investigator) throughout this study
- •Treatment with an investigational agent or device within 30 days before
- •enrollment or scheduled to receive an investigational agent other than those
- •specified by this protocol during the course of this study
- •Subject has known sensitivity to any of the products to be administered during dosing
- •Grand mal seizure within 6 months before enrollment
- •Upper or lower GI bleeding within 6 months before enrollment
- •Currently receiving immunosuppressive therapy
研究者
相似试验
进行中（未招募）
1 期
A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving DialysisAnemia in subjects with chronic kidney disease not receiving dialysisEUCTR2006-003173-27-FRAmgen Limited155
进行中（未招募）
不适用
A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease Not Receiving Dialysis - Darbepoetin Alfa 20060163Treatment of anemia in CKD subjects not receiving dialysisMedDRA version: 8.1Level: LLTClassification code 10002073Term: Anaemia of chronic diseaseEUCTR2006-003173-27-ITAMGEN S.P.A.155
尚未招募
Unknown
A multi-center, single-arm clinical study for the efficacy and safety of '10THERMA' on tissue coagulation and skin rejuvenatioFactors influencing health status and contact with health servicesKCT0008709Korean Society for Laser Medicine and Sugery31
招募中
1 期
To evaluate the safety tolerability and performance of the liver assist device (EBDLR System) in patients suffering from Acute Liver FailureCTRI/2024/02/062612Ykrita Life sciences Pvt Ltd.
进行中（未招募）
不适用
Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancerEUCTR2011-001720-37-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO